Natural history of Danon disease

Genetics in Medicine

Volumn 13, Issue 6, 2011, Pages 563-568

  Boucek, Dana ^a   Jirikowic, Jean ^a   Taylor, Matthew ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Mailstop F442 ^*  (United States)

Author keywords

cardiomyopathy; Danon disease; genetics; Wolff Parkinson White syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; COGNITIVE DEFECT; CREATINE KINASE BLOOD LEVEL; DANON DISEASE; FEMALE; GENE MUTATION; GENETIC SCREENING; HEART PALPITATION; HEART TRANSPLANTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYOPATHY; NEUROPATHY; PHENOTYPE; PROGNOSIS; SEX DIFFERENCE; THORAX PAIN; WOLFF PARKINSON WHITE SYNDROME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC COUNSELING; GLYCOGEN STORAGE DISEASE TYPE IIB; HUMANS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; MUSCLE WEAKNESS; PHENOTYPE; SEX FACTORS;

EID: 79959221248     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31820ad795     Document Type: Article

References (25)

1. Danon MJ, Oh SJ, DiMauro S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981;31:51-57. (Pubitemid 11217453)
2. Fanin M, Nascimbeni AC, Fulizio L, Spinazzi M, Melacini P, Angelini C. Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol 2006;168:1309-1320.
3. Lacoste-Collin L, Garcia V, Uro-Coste E, et al. Danon's disease (X-linked vacuolar cardiomyopathy and myopathy): a case with a novel Lamp-2 gene mutation. Neuromuscul Disord 2002;12:882-885.
4. Prall FR, Drack A, Taylor M, et al. Ophthalmic manifestations of Danon disease. Ophthalmology 2006;113:1010-1013. (Pubitemid 43795242)
5. Schorderet DF, Cottet S, Lobrinus JA, Borruat FX, Balmer A, Munier FL. Retinopathy in Danon disease. Arch Ophthalmol 2007;125:231-236.
6. Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002;58:1773-1778. (Pubitemid 34663577)
7. Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000;406: 906-910. (Pubitemid 30664268)
8. Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009;301:1253-1259.
9. Echaniz-Laguna A, Mohr M, Epailly E, et al. Novel Lamp-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease. Muscle Nerve 2006;33:393-397.
10. Lobrinus JA, Schorderet DF, Payot M, et al. Morphological, clinical and genetic aspects in a family with a novel LAMP-2 gene mutation (Danon disease). Neuromuscul Disord 2005;15:293-298. (Pubitemid 40431934)
11. Taylor MR, Ku L, Slavov D, et al. Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J Hum Genet 2007;52:830-835. (Pubitemid 47512855)
12. Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 2005; 112:1612-1617. (Pubitemid 41324523)
13. Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 2004;90:842-846. (Pubitemid 39005922)
14. Balmer C, Ballhausen D, Bosshard NU, et al. Familial X-linked cardiomyopathy (Danon disease): diagnostic confirmation by mutation analysis of the LAMP2gene. Eur J Pediatr 2005;164:509-514. (Pubitemid 41073818)
15. Regelsberger G, Hoftberger R, Pickl WF, et al. Danon disease: case report and detection of new mutation [published online ahead of print July 7, 2009]. J Inherit Metab Dis doi: 10.1007/s10545-009-1097-9.
16. Fanin M, Nascimbeni AC, Fulizio L, Spinazzi M, Melacini P, Angelini C. Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol 2006;168:1309-1320.
17. Dougu N, Joho S, Shan L, et al. Novel LAMP-2 mutation in a family with Danon disease presenting with hypertrophic cardiomyopathy. Circ J 2009; 73:376-380.
18. Sabourdy F, Michelakakis H, Anastasakis A, et al. Danon disease: further clinical and molecular heterogeneity. Muscle Nerve 2009;39:837-844.
19. Sugie K, Koori T, Yamamoto A, et al. Characterization of Danon disease in a male patient and his affected mother. Neuromuscul Disord 2003;13:708-711. (Pubitemid 37249488)
20. Nadeau A, Therrien C, Karpati G, Sinnreich M. Danon disease due to a novel splice mutation in the LAMP2 gene. Muscle Nerve 2008;37:338-342. (Pubitemid 351304793)
21. Takahashi M, Yamamoto A, Takano K, et al. Germline mosaicism of a novel mutation in lysosome-associated membrane protein-2 deficiency (Danon disease). Ann Neurol 2002;52:122-125. (Pubitemid 34693757)
22. Bertini E, Donati MA, Broda P, et al. Phenotypic heterogeneity in two unrelated Danon patients associated with the same LAMP-2 gene mutation. Neuropediatrics 2005;36:309-313. (Pubitemid 41501117)
23. Burusnukul P, de Los Reyes EC, Yinger J, Boue DR. Danon disease: an unusual presentation of autism. Pediatr Neurol 2008;39:52-54. (Pubitemid 351794415)
24. Musumeci O, Rodolico C, Nishino I, et al. Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene. Neuromuscul Disord 2005;15:409-411. (Pubitemid 40723623)
25. Di Blasi C, Jarre L, Blasevich F, Dassi P, Mora M. Danon disease: a novel LAMP2 mutation affecting the pre-mRNA splicing and causing aberrant transcripts and partial protein expression. Neuromuscul Disord 2008;18: 962-966.